Expanded Access Programs

Early access program services

Sciensus helps pharmaceutical companies navigate the complexities of Early Access Programs (EAPs), ensuring that eligible patients receive life-changing treatments before full market approval. Our regulatory, distribution, and patient engagement expertise enables a faster, compliant, and seamless route to market across Europe and beyond.

Sciensus have a 30-year proven track record in European market expansion, and over 4,000 relationships with wholesalers, hospitals, pharmacies, and clinics, allowing us to quickly gain access to prescribing physicians.

Schedule a free consultation

What is an early access program?

An early access program, also known as an expanded access program, is a regulatory pathway that enables companies to widen potentially lifesaving access to investigational and pre-approval medication. By allowing a broader patient population to receive promising treatments before full approval, early access programs can result in accelerating adoption and generating diverse real-world data. In these cases, the patient does not have comparable or satisfactory alternative therapies available and cannot participate in a clinical trial.

For rare disease patients, early access programs are a crucial lifeline, providing access to innovative therapies that may not yet be available in their home country.

Early access programs can be launched at any stage of the product lifecycle, including:

  • Before full regulatory approval to help generate real-world data
  • After a product is discontinued to maintain patient access

Different types of early access programs

Early access programs can generally be categorised into two main types:

  • Named Patient Programs (NPP) – Designed to provide access to a specific, unapproved drug for an individual patient, often on a case-by-case basis
  • Compassionate Use Programs (CUP) – Broader initiatives that allow access to investigational drugs for a group of patients facing serious or life-threatening conditions

Benefits for pharma and biotech companies 

As well as supporting clinicians to meet the needs of their patients ethically and compliantly, an EAP can help pharma and biotech companies to achieve:

White_Location

Faster access to new global markets

Forecasters estimate the European rare market will reach more than $60 billion in value by as early as 2028, representing a near 50% increase in the space of five years.

White_Two-accounts

Network building with clinicians and PAGs

Early adopting clinicians can become future brand advocates for the manufacturer, supporting discussions with regulators based on their experience of use.  

White_Document

Collection of valuable real-world data

EAP participants are more representative of real-world patients. The real-world data collected during an EAP can inform future development and commercialisation strategies.

expanded access program

Expanded access program vs. clinical trials

Clinical trials for rare disease therapies, as well as more prevalent speciality care illnesses can be infrequent and challenging for several practical and ethical reasons. Early access programs can be an attractive alternative for companies who wish to widen potentially lifesaving access for patients who are not eligible for a clinical trial. Unlike clinical trials, early access programs:

  • Do not have strict eligibility criteria, making access easier for a broader population
  • Allow patients to live their daily lives while receiving treatment
  • Still involve monitoring for safety and efficacy but in a real-world setting

Early access programs in Europe: challenges and solutions

Gaining approval for an early access program in Europe can be challenging and costly, with multiple complex regulatory landscapes and different healthcare systems to negotiate across the many member states.

  • Regulatory complexity – Each country has different EAP rules and approval processes
  • Strict promotion restrictions – Unlicensed medicines cannot be actively marketed, so all requests must be unsolicited
  • Potential risks – Adverse events or poor patient adherence could impact future commercialisation
European drug approval
Key challenges:
  • Regulatory complexity – Each country has different EAP rules and approval processes
  • Strict promotion restrictions – Unlicensed medicines cannot be actively marketed, so all requests must be unsolicited
  • Potential risks – Adverse events or poor patient adherence could impact future commercialisation
European drug approval
Sciensus’ solution:
  • Country-specific regulatory expertise – We handle approvals across Europe
  • Compliance-first approach – Ensuring all interactions align with promotional restrictions
  • Risk mitigation strategies – Implementing safety monitoring & adherence programs

Accelerate your biotech strategy – unlock early access in Europe today

Our fully integrated expanded access services

A comprehensive regulatory assessment

We will support you with a regulatory assessment of the countries where you are interested in running an early access program. This will include advice on the most suitable program type, whether it can be charged for, and the data you may be able to collect.

A digital platform for clinicians

We will ensure healthcare professionals are properly validated and given access to our online ordering portals: Sciensus Axcess and Sciensus Connect Registered HCPs will be able to view documentation for the access program including product information and any relevant training materials.

An established supply chain

We operate a GDP-certified medical warehouse hub in the Netherlands, equipped for all temperature regimes, facilitating delivery to most European sites within 24 to 48 hours. In the UK we have 2 GDP-certified warehouses, with 15 national hubs. We will ensure there is full track-and-trace capability to allow auditing of all activity.

 

 

Digitally enabled Patient Support Programs

We deliver global Patient Support Programs (PSP), both face-to-face and remotely, through highly qualified HCPs. We understand regulatory frameworks and can mobilise our clinical workforce to assess needs, research conditions, and develop tailored PSPs for your product.

A dedicated account manager

We provide a personal touch thanks to a dedicated account manager, a bespoke solution tailored to your specific needs, a strategy developed by our Director of Early Access Programs or Business Development Director with therapy specialism, supported by a dedicated team that will implement it for you.

How to get started

Step 1: Schedule a consultation with our EAP regulatory experts.

Step 2: Define the program scope, including eligibility, distribution, and safety monitoring.

Step 3: Sciensus handles logistics, compliance, and patient engagement.

Step 4: Monitor real-world data and refine access strategies.

Schedule a free consultation

Why partner with Sciensus?

Streamlined regulatory approval

Expert navigation of complex national regulations to accelerate approvals

Faster patient access

Ensuring eligible patients receive life-changing treatments without delays

End-to-end EAP management

From regulatory submissions to patient engagement, distribution, and safety monitoring

Data-driven insights

Real-world data collection to support market access and future approvals.